🗝️ Key Points

💉 Hydrocortisone Saves Lives:
The 2023 Cape Cod Trial (NEJM) showed a clear mortality benefit and reduced need for intubation in severe CAP patients treated with hydrocortisone.
📊 Guidelines Are Catching Up:
The SCCM (2024) and ERS now recommend steroids for severe CAP, while ATS/IDSA updates are still pending.
🔥 Redefining “Severe”:
Patients requiring high FiO₂ (>50%), noninvasive or mechanical ventilation, or PSI >130 meet criteria for steroid therapy — even outside the ICU.
🍬 Main Risk = Hyperglycemia:
Elevated glucose was the most consistent adverse effect, but rates of GI bleed and secondary infection were not increased.
🧭 Early, Targeted Use Matters:
Start hydrocortisone within 24 hours of identifying severity — especially in patients with high CRP (>150) or strong inflammatory response.

Click here for Direct Download of the Podcast.

📝 Introduction

Corticosteroids have long sparked debate in the treatment of bacterial pneumonia — once viewed with skepticism, now increasingly supported by high-quality evidence. In this episode, Dr. Alex Chapa joins the REBEL Core Cast team to explore how the 2023 Cape Cod Trial (NEJM) reshaped practice and guideline recommendations for severe community-acquired pneumonia (CAP).

📖 Historical Context & Long-Standing Skepticism

For decades, the use of ster...

🧭 REBEL Rundown

🗝️ Key Points

📝 Introduction

📖 Historical Context & Long-Standing Skepticism